Considering the conflicting nature of data regarding BCSC phenotypes, it is important to systematically investigate the expression of CD44, CD24 and ALDH1A1 in different breast cancer subtypes to understand whether the expression of these biomarkers indeed correlates with tumorigenic potential. The gene discussed is CD24; the disease is breast carcinoma.